These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25052742)

  • 1. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank.
    Caster O; Juhlin K; Watson S; Norén GN
    Drug Saf; 2014 Aug; 37(8):617-28. PubMed ID: 25052742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use.
    Caster O; Sandberg L; Bergvall T; Watson S; Norén GN
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):1006-1010. PubMed ID: 28653790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
    Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
    Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
    Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
    Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
    Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prediction model-based algorithm for computer-assisted database screening of adverse drug reactions in the Netherlands.
    Scholl JHG; van Hunsel FPAM; Hak E; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):199-205. PubMed ID: 29271017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project.
    Caster O; Dietrich J; Kürzinger ML; Lerch M; Maskell S; Norén GN; Tcherny-Lessenot S; Vroman B; Wisniewski A; van Stekelenborg J
    Drug Saf; 2018 Dec; 41(12):1355-1369. PubMed ID: 30043385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre.
    Star K; Sandberg L; Bergvall T; Choonara I; Caduff-Janosa P; Edwards IR
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):680-689. PubMed ID: 30767342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports.
    Liu R; Zhang P
    BMC Med Inform Decis Mak; 2019 Dec; 19(1):279. PubMed ID: 31849321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.
    Fusaroli M; Salvo F; Begaud B; AlShammari TM; Bate A; Battini V; Brueckner A; Candore G; Carnovale C; Crisafulli S; Cutroneo PM; Dolladille C; Drici MD; Faillie JL; Goldman A; Hauben M; Herdeiro MT; Mahaux O; Manlik K; Montastruc F; Noguchi Y; Norén GN; Noseda R; Onakpoya IJ; Pariente A; Poluzzi E; Salem M; Sartori D; Trinh NTH; Tuccori M; van Hunsel F; van Puijenbroek E; Raschi E; Khouri C
    Drug Saf; 2024 Jun; 47(6):575-584. PubMed ID: 38713346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of consumer reporting on signal detection: using disproportionality analysis.
    Hammond IW; Rich DS; Gibbs TG
    Expert Opin Drug Saf; 2007 Nov; 6(6):705-12. PubMed ID: 17967159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance.
    Lee I; Lee TA; Crawford SY; Kilpatrick RD; Calip GS; Jokinen JD
    Expert Opin Drug Saf; 2020 Oct; 19(10):1357-1366. PubMed ID: 32662668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class-imbalanced subsampling lasso algorithm for discovering adverse drug reactions.
    Ahmed I; Pariente A; Tubert-Bitter P
    Stat Methods Med Res; 2018 Mar; 27(3):785-797. PubMed ID: 27114328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a multivariate prediction model to identify individual case safety reports which require clinical review.
    Gosselt HR; Bazelmans EA; Lieber T; van Hunsel FPAM; Härmark L
    Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1300-1307. PubMed ID: 36251280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development and evaluation of triage algorithms for early discovery of adverse drug interactions.
    Strandell J; Caster O; Hopstadius J; Edwards IR; Norén GN
    Drug Saf; 2013 May; 36(5):371-88. PubMed ID: 23640657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.